If the European Commission approves this treatment, it'll be the first HER2-targeted agent for HER2-positive biliary tract cancer available to patients in the EU.

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion ...